| Literature DB >> 27884312 |
Vlado Perkovic1, Rajiv Agarwal2, Paola Fioretto3, Brenda R Hemmelgarn4, Adeera Levin5, Merlin C Thomas6, Christoph Wanner7, Bertram L Kasiske8, David C Wheeler9, Per-Henrik Groop10.
Abstract
The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.Entities:
Keywords: antidiabetic agents; cardiovascular disease; chronic kidney disease; diabetes; glycemic control; renoprotection
Mesh：
Year: 2016 PMID： 27884312 DOI： 10.1016/j.kint.2016.09.010
Source DB: PubMed Journal: Kidney Int ISSN： 0085-2538 Impact factor: 10.612